Skip to Main Content

Paper Details

MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges.
Neuro Oncol
153
2019
GBM, Glioblastoma, MGMT, MGMT promoter, O6-methylguanine, O6-methylguanine-DNA methyl-transferase, O6-methylguanine-DNA methyl-transferase (MGMT) gene promoter, glioblastoma, malignant brain tumor, patient
Author NameAffiliation
Farshad NassiriUniversity of Toronto
Farshad NassiriPrincess Margaret Cancer Centre, University Health Network
Patrick Y WenCenter for Neuro-Oncology, Dana-Farber Cancer Institute
Minesh P MehtaMiami Cancer Institute
Roger StuppMalnati Brain Tumor Institute of the Lurie Cancer Center, Northwestern University Feinberg School of Medicine
Kenneth AldapeCenter for Cancer Research, National Cancer Institute
Kenneth AldapeCenter for Cancer Research, National Cancer Institute
Gelareh ZadehUniversity of Toronto
Gelareh ZadehPrincess Margaret Cancer Centre, University Health Network
Gelareh ZadehToronto Western Hospital, University Health Network
  • 1 - 10

Datasets

Release 1.2